1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
0
Active Trials
200 recruiting
1
Rare Diseases
across 2 areas
0
News (30d)
Quiet
Omex International, Inc. is a company with 1 orphan drug designation across 1 rare disease. gene therapy candidates in 1 disease. 19 active policy bills affect their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| sickle cell disease | Synthetic derivative of 16-hydroxy-9Z, 12Z, 14E-octadecatrienoic acid | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
1/1
candidate diseases
0
avg importance: 0
19
affecting portfolio
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
1/1
candidate diseases
0
avg importance: 0
19
affecting portfolio